Brink Biologics

Executive Summary

Brink Biologics, an affiliate of ImmunityBio, Inc., is a specialized biotechnology solutions company focused on providing standardized, engineered Natural Killer (NK-92) cell lines for bioanalytical testing. Its proprietary Neukopanel® product line and related research services support pharmaceutical and biotech clients in drug discovery, development, and manufacturing quality control. By offering consistent and reproducible cell-based assays, Brink Biologics addresses a critical need in the validation and release testing of biologics, particularly in the rapidly growing fields of immuno-oncology and cell therapy. The company's San Diego base positions it within a major biotech hub, facilitating collaboration and client access. As the demand for high-quality cell lines in drug development intensifies, Brink Biologics is well-positioned to expand its customer base and product offerings. Its affiliation with ImmunityBio provides strategic backing and potential synergies in advanced therapeutics. Upcoming catalysts include the introduction of new Neukopanel variants tailored for specific assay types, formation of partnerships with major pharmaceutical companies for use in pivotal clinical trials, and potential adoption of its cell lines in regulatory-compliant manufacturing quality control workflows. These developments could significantly enhance the company's revenue trajectory and market presence.

Upcoming Catalysts (preview)

• TBDCommercial launch of new Neukopanel product variants70% success
• TBDStrategic collaboration with a top pharmaceutical company for clinical trial use60% success
• TBDExpansion into cell therapy manufacturing QC services55% success